SCHEMBL289958

SCHEMBL289958

C/C=C\CCc1cccc(CC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.46
GPR52 Q9Y2T5 9/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
PPARG P37231 1/20 0.41
SELL P14151 1/20 0.41
SELP P16109 1/20 0.41
SELE P16581 1/20 0.41
GLS O94925 1/20 0.41
PTPRB P23467 1/20 0.40
CDC25A P30304 1/20 0.40
CDC25B P30305 1/20 0.40
PTEN P60484 1/20 0.40
PTPMT1 Q8WUK0 1/20 0.40
KDM4E B2RXH2 1/20 0.40
RGS12 O14924 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289960 1.00 AKR1B1 (0.46) AKR1B1GPR52CYP1A2CYP2C19PPARG
SCHEMBL290358 0.83 SLC7A5 (0.51) GPR52KDM4ELMNAGAAMAPT
SCHEMBL1628157 0.83 SLC7A5 (0.51) GPR52KDM4ELMNAGAAMAPT
SCHEMBL290357 0.83 SLC7A5 (0.51) GPR52KDM4ELMNAGAAMAPT
SCHEMBL11892098 0.82 SLC7A5 (0.41) GPR52PPARA
SCHEMBL10985017 0.81 AKR1B1 (0.50) AKR1B1CYP1A2CYP2C19SELLSELP
SCHEMBL20259161 0.81 SLC7A5 (0.40) GPR52KDM4ELMNAPPARA
SCHEMBL4402323 0.80 AKR1B1 (0.62) AKR1B1CYP1A2CYP2C19SELLSELP
SCHEMBL30638471 0.79 KEAP1 (0.63) AKR1B1CYP1A2CYP2C19SELLSELP
SCHEMBL4407150 0.79 KEAP1 (0.63) AKR1B1CYP1A2CYP2C19SELLSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
EP-3443957-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER LIMINAL BIOSCIENCES LTD (GB) 2020-11-25 EP disclosed
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2020-10-27 US disclosed
EP-3443957-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC PHARMA SMT LIMITED (GB) 2019-02-20 EP disclosed
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LIMITED (GB) 2018-06-14 US disclosed
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LIMITED (GB) 2018-06-14 US disclosed
US-9938221-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2018-04-10 US disclosed
US-9938221-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2018-04-10 US disclosed
US-9439882-B2 Compounds and compositions for the treatment of cancer PROMETIC BIOSCIENCES INC. (CA) 2016-09-13 US disclosed
EP-2427416-B1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC PHARMA SMT LTD (GB) 2016-03-09 EP disclosed
EP-2632452-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER ProMetic BioSciences Inc. (CA) 2013-09-04 EP disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
WO-2012097427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC BIOSCIENCES INC. (CA) 2012-07-26 WO disclosed
WO-2012097427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC BIOSCIENCES INC. (CA) 2012-07-26 WO disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
EP-2427416-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF ProMetic BioSciences Inc. (CA) 2012-03-14 EP disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162799-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF TYR, PAH, REN AKR1B1 36/4885GPR52 1429/4885CYP1A2 76/4885
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer DCK, TOP2B, TOP2A AKR1B1 454/4885GPR52 3452/4885CYP1A2 991/4885
US-10815183-B2 Substituted aromatic compounds and pharmaceutical uses thereof TYR, PAH, REN AKR1B1 36/4885GPR52 1429/4885CYP1A2 76/4885
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof TYR, PAH, REN AKR1B1 36/4885GPR52 1429/4885CYP1A2 76/4885
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof TYR, PAH, REN AKR1B1 36/4885GPR52 1429/4885CYP1A2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.